Successful treatment with fumagillin of the first pediatric case of digestive microsporidiosis in a liver-kidney transplant.

Abstract

We report the first successful use, to our knowledge, of fumagillin alone in a pediatric patient to cure intestinal microsporidiosis in a liver-kidney transplanted child. Detection of Enterocytozoon bieneusi in stool became negative from the first post-therapeutic control, while digestive symptoms disappeared in 4 days. During a 9-month follow-up, polymerase chain reaction and direct examinations remained negative for microsporidia in her feces. No major undesirable effects were noted during the anti-microsporidial therapy.

• Authors: G Desoubeaux, Z Maakaroun-Vermesse, C Lier, E Bailly, F Morio, F Labarthe, L Bernard, J Chandenier
• Journal: Transplant infectious disease : an official journal of the Transplantation Society (Transpl Infect Dis) Vol. 15 Issue 6 Pg. E250-9 (Dec 2013) ISSN: 1399-3062 [Electronic] Denmark
• PMID: 24298986 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antifungal Agents
• Cyclohexanes
• Fatty Acids, Unsaturated
• Sesquiterpenes
• fumagillin

Topics

• Antifungal Agents (therapeutic use)
• Child
• Child, Preschool
• Cyclohexanes (therapeutic use)
• Diarrhea (microbiology)
• Enterocytozoon (genetics, isolation & purification)
• Fatty Acids, Unsaturated (therapeutic use)
• Feces (microbiology)
• Female
• Humans
• Kidney Transplantation (adverse effects)
• Liver Transplantation (adverse effects)
• Microsporidiosis (drug therapy, microbiology)
• Sesquiterpenes (therapeutic use)